Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 18/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 14/20 | 0.50 |
| ▸ | PDE4A | P27815 | 12/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 12/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL852053 | 1.00 | PDE4B (0.50) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL146817 | 1.00 | PDE4B (0.50) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL5184516 | 0.89 | PDE4B (0.52) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL7414607 | 0.89 | PDE4B (0.54) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL7414604 | 0.89 | PDE4B (0.54) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL7786887 | 0.89 | PDE4B (0.54) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL6197797 | 0.88 | PDE4B (0.59) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL6196613 | 0.88 | PDE4B (0.59) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL6196611 | 0.88 | PDE4B (0.59) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL5306792 | 0.87 | PDE4B (0.53) | PDE4BPDE4DPDE4APDE4CABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1241 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2828242-B1 | NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYLATE AS AGONIST OF THE ß2 ADRENERGIC RECEPTOR. | ALMIRALL SA (ES) | 2017-10-04 | — | — | EP | claimed |
| US-9737521-B2 | Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor | RHIZEN PHARMACEUTICALS SA (CH) | 2017-08-22 | — | — | US | claimed |
| EP-1305329-B2 | 6.ALPHA.,9.ALPHA.-DIFLUORO-17.ALPHA.-(2-FURANYLCARBOXYL)OXY-11.BETA.-HYDROXY-16.ALPHA.-METHYL-3-OXO-ANDROST-1,4-DIENE-17-CARBOTHIOIC ACID S-FLUOROMETHYL ESTER AS AN ANTI-INFLAMMATORY AGENT | GLAXO GROUP LTD (GB) | 2015-03-18 | — | — | EP | claimed |
| EP-2834219-A1 | SALTS OF 5-[(1R)-2-({2-[4-(2,2-DIFLUORO-2-PHENYLETHOXY)PHENYL]ETHYL}AMINO)-1-HYDROXYETHYL]-8-HYDROXYQUINOLIN-2(1H)-ONE | Almirall S.A. (ES) | 2015-02-11 | — | — | EP | claimed |
| EP-2828242-A1 | NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYLATE AS AGONIST OF THE ß2 ADRENERGIC RECEPTOR. | Almirall S.A. (ES) | 2015-01-28 | — | — | EP | claimed |
| WO-2013149959-A1 | SALTS OF 5-[(1R)-2-({2-[4-(2,2-DIFLUORO-2-PHENYLETHOXY)PHENYL]ETHYL}AMINO)-1-HYDROXYETHYL]-8-HYDROXYQUINOLIN-2(1H)-ONE | ALMIRALL, S.A. (ES) | 2013-10-10 | — | — | WO | claimed |
| WO-2013139712-A1 | NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYLATE AS AGONIST OF THE β2 ADRENERGIC RECEPTOR. | ALMIRALL, S.A. (ES) | 2013-09-26 | — | — | WO | claimed |
| EP-2641900-A1 | Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor. | Almirall, S.A. (ES) | 2013-09-25 | — | — | EP | claimed |
| EP-2367796-B1 | MESYLATE SALT OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO }-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR | ALMIRALL SA (ES) | 2012-10-24 | — | — | EP | claimed |
| US-8273894-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2012-09-25 | — | — | US | claimed |
| WO-2008095720-A1 | NAPADISYLATE SALT OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. (ES) | 2008-08-14 | — | — | WO | claimed |
| US-20080051379-A1 | Compositions and Methods for the Treatment of Peripheral B-Cell Neoplasms | TRUSTEES OF BOSTON UNIVERSITY (US) | 2008-02-28 | — | — | US | claimed |
| EP-1305329-B1 | 6.ALPHA.,9.ALPHA.-DIFLUORO-17.ALPHA.-(2-FURANYLCARBOXYL)OXY-11.BETA.-HYDROXY-16.ALPHA.-METHYL-3-OXO-ANDROST-1,4-DIENE-17-CARBOTHIOIC ACID S-FLUOROMETHYL ESTER AS AN ANTI-INFLAMMATORY AGENT | GLAXO GROUP LTD (GB) | 2007-12-05 | — | — | EP | claimed |
| EP-1781298-A1 | PHARMACEUTICAL COMBINATIONS CONTAINING BENZOXAZINE FOR TREATING RESPIRATORY DISEASES | Boehringer Ingelheim International GmbH (DE) | 2007-05-09 | — | — | EP | claimed |
| US-7101866-B2 | 6,9-Difluoro-17 alpha -((2-furanylcarbonyl)oxy)-11 beta -hydroxy-16 alpha -methyl-3-oxo-androsta-1,4-diene-17 beta -carbothioic acid S-fluoromethyl ester; antiinflammatory agents for the treatment of allergic conditions | GLAXO GROUP LIMITED (GB) | 2006-09-05 | — | — | US | claimed |
| WO-2006062817-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERIPHERAL B-CELL NEOPLASMS | BOSTON MEDICAL CENTER CORPORATION (US) | 2006-06-15 | — | — | WO | claimed |
| WO-2005102349-A1 | PHARMACEUTICAL COMBINATIONS CONTAINING BENZOXAZINE FOR TREATING RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | WO | claimed |
| US-20050043343-A1 | Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-24 | — | — | US | claimed |
| US-20050026886-A1 | Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-03 | — | — | US | claimed |
| EP-0636026-B1 | COMPOUNDS USEFUL FOR TREATING INFLAMMATORY DISEASES AND INHIBITING PRODUCTION OF TUMOR NECROSIS FACTOR | SMITHKLINE BEECHAM CORP (US) | 2001-12-05 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026886-A1 | Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor | PDE12, PDE3A, PDE3B | PDE4B 5/4885PDE4D 15/4885PDE4A 6/4885 |
| US-20050043343-A1 | Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor | PDE3A, PDE4B, PDE12 | PDE4B 2/4885PDE4D 16/4885PDE4A 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.